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Abstract
Rationale Using the drinking-in-the-dark (DID) model, we
compared the effects of a novel mu-opioid receptor antagonist,
GSK1521498, with naltrexone, a licensed treatment of alco-
hol dependence, on ethanol consumption in mice.
Objective We test the ability of GSK1521498 to reduce alco-
hol consumption and compare its intrinsic efficacy to that of
naltrexone by comparing the two drugs at doses matched for
equivalent receptor occupancy.
Methods Thirty-six C57BL/6J mice were tested in a DID pro-
cedure. In 2-day cycles, animals experienced one baseline,
injection-free session, and one test session when they received
two injections, one of test drug and one placebo. All animals
received GSK1521498 (0, 0.1, 1 and 3 mg/kg, i.p., 30 min
pre-treatment) and naltrexone (0, 0.1, 1 and 3 mg/kg, s.c.
10 min pre-treatment) in a cross-over design. Receptor
occupancies following the same doses were determined
ex vivo in separate groups by autoradiography, using
[3H]DAMGO. Binding in the region of interest was measured
integrally by computer-assisted microdensitometry and
corrected for non-specific binding.
Results Both GSK1521498 and naltrexone dose-dependently
decreased ethanol consumption. When drug doses were
matched for 70–75 % receptor occupancy, GSK1521498
3 mg/kg, i.p., caused a 2.5-fold greater reduction in alcohol
consumption than naltrexone 0.1 mg/kg, s.c. Both
GSK1521498 and naltrexone significantly reduced sucrose
consumption at a dose of 1 mg/kg but not 0.1 mg/kg. In a test
of conditioned taste aversion, GSK1521498 (3 mg/kg) re-
duced sucrose consumption 24 h following exposure to a con-
ditioning injection.
Conclusions Both opioid receptor antagonists reduced alco-
hol consumption but GK1521498 has higher intrinsic efficacy
than naltrexone.
Keywords Naltrexone . Drinking-in-the-dark . Receptor
occupancy . Inverse agonist . Mu-opioid receptor
Introduction
Alcoholism is a complex heterogeneous disorder, for which
there are currently limited treatment options. While it is
routine for alcohol dependent patients to undergo clinically
supervised detoxifications, maintaining abstinence is fre-
quently unsuccessful, leading to successive repeated epi-
sodes of further detoxification and relapse, with ever-
increasing difficulty in maintaining abstinence (Loeber
et al. 2010). One of the few strategies currently licensed
for reducing relapse is the blockade of mu-opioid receptors
(Kiefer et al. 2003; Volpicelli et al. 1992). Although there is
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good evidence that naltrexone significantly reduces the risk
of drinking (Monti et al. 1999), the overall effectiveness is
limited, with risk of relapse showing only a moderate de-
cline from an untreated relapse risk of 1.00 to a relative risk
of 0.83 (Rosner et al. 2010). In the majority of studies pub-
lished, naltrexone reduces significantly the rates of drink-
ing in heavy drinkers by 30–60 %. While naltrexone re-
duces craving significantly, abstinence is achieved usually
in only 25–35 % of cases (Pettinati et al. 2006). The most
recent meta-analysis (Donoghue et al. 2015) found that the
risk of individuals returning to any drinking at approxi-
mately 3 months was significantly reduced for the naltrex-
one group (RR=0.92, 95 % CI=0.86–1.00) as was the risk
of individuals relapsing to heavy drinking at 3 months
(RR=0.85, 95 % CI=0.78–0.93).
Nevertheless, the therapeutic utility of naltrexone in alco-
hol dependence is limited, perhaps as a result of clinical and
genetic heterogeneity: e.g. effects of naltrexone are stronger in
the subgroup of alcoholic patients carrying the Asp variant of
the mu-opioid receptor (OPRM1) A1118G SNP (Oslin et al.
2003). It may also be relevant that naltrexone is rapidly
metabolised to 6-β-naltrexol and that both these drugs have
partial agonist activity at mu-opioid receptors under some as-
say conditions (Kelly et al. 2014). It is also notable that ad-
herence to naltrexone treatment is poor, and this is often at-
tributable to adverse events including nausea and vomiting (de
Wit et al. 1999).
GSK1521498 is a novel mu-opioid receptor antagonist
that is being developed for disorders of compulsive reward-
driven behaviour. Using recombinant human opioid recep-
tors , we have previously observed in vi t ro that
GSK1521498 is a selective mu-opioid receptor antagonist
with approximately 14-fold selectivity for mu over both
delta- and kappa-opioid receptor subtypes (Ignar et al
2011; Kelly et al 2014). Compared to naltrexone,
GSK1521498 was more selective for the mu-opioid recep-
tor and had greater affinity for mu-opioid receptor binding.
We also observed that whereas GSK1521498 could
completely antagonize mu-opioid receptor activation by
an exogenous agonist challenge, naltrexone, naloxone,
and 6-β-naltrexol could achieve only about 70 % blockade
even at high doses, and whereas GSK1521498 had slight
inverse agonist activity, naltrexone had partial agonist ac-
tivity, in cell lines overexpressing mu-opioid receptors
(Ignar et al. 2011; Kelly et al. 2014). The human pharma-
cokinetics and brain receptor occupancy of GSK1521498
are not so directly relevant to this study but have been re-
ported elsewhere in comparison to naltrexone and 6-β-
naltrexol (Nathan et al. 2012a, b; Rabiner et al. 2011).
The behavioural effects of GSK1521498 have been report-
ed using second-order reinforcement schedules to elicit
drug-seeking behaviour in rats trained to work for self-
administration of heroin or cocaine (Giuliano et al. 2013).
At equivalent doses to those used in the current study,
GSK1521498 demonstrated significantly greater efficacy
than naltrexone in inhibiting drug-seeking behaviour for
cocaine and heroin rewards.
Here, we aimed to test the intrinsic efficacy of
GSK1521498 for the first time in an animal model of alco-
hol consumption, and, specifically, to compare the efficacy
of GSK1521498 to that of naltrexone with the two drugs
matched both for dose and for receptor occupancy. The
drinking-in-the dark (DID) paradigm has been shown to
be an effective way to induce alcohol consumption (Hwa
et al. 2011; Ripley and Stephens 2011). In this model,
C57BL/6J mice, which are genetically predisposed to drink
ethanol, are given access to 20 % ethanol solution, replac-
ing their water bottles, for 2 h beginning 3 h after the start of
their dark phase. In the majority of animals, this leads to an
ethanol intake that produces high blood ethanol levels and
signs of behavioural intoxication (Rhodes et al. 2007). This
model has been evaluated using drugs that have been shown
to reduce ethanol consumption in other animal models and
in humans. Naltrexone has been shown to be efficacious in
this model (Kamdar et al. 2007) with doses of 0.5, 1, or
2 mg/kg dose-dependently decreasing ethanol consumption
without significant effect on the consumption of plain water
or 10 % sugar water. On the basis of the prior pharmaco-
logical and behavioural data on GSK1521498, we predicted
hypothetically that it would also reduce alcohol consump-
tion in this model and that it would have higher intrinsic
efficacy than naltrexone.
In the first experiment, we compared the effects of
GSK1521498 and naltrexone on ethanol consumption in
ethanol-experienced C57BL/6J male mice. To control for
non-specific effects of both compounds, we also examined
the effects of GSK1521498 and naltrexone on consumption
of a sucrose solution in the same experiment. Decreases in
consumption of ethanol could be due to non-specific ef-
fects, such as general malaise following the injection, and
there is some evidence to suggest that naltrexone may also
produce a conditioned taste aversion (CTA) at relatively
low doses (Parker and Rennie 1992). In a second experi-
ment, we therefore tested GSK1521498 in a CTA paradigm
and compared it against a standard dose of lithium chloride.
Finally, in order to evaluate possible differences in intrinsic
efficacy of GSK1521498 and naltrexone with the drugs
matched for receptor occupancy, we additionally quantified
binding of GSK1521498 and naltrexone binding to mu-
opioid receptors (MOPr) in mouse brain using autoradiog-
raphy. We reasoned that demonstrating a superior behav-
ioural effect of GSK1521498 versus naltrexone at equiva-
lent levels of receptor occupancy would provide more rig-
orous evidence of greater intrinsic efficacy of GSK1521498
than a comparison matched in terms of administered doses
(Jones et al. 1994).
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Materials and methods
Animals
In all studies, C57BL/6J male mice (Charles River, Margate,
UK), weighing approximately 20 g at the start of the experi-
ment, were singly housed in standard caging containing saw-
dust and corrugated paper bedding material. Mice had ad
libitum access to food (Purina lab chow) and water throughout
the experiment unless otherwise stated. The facility was main-
tained at a temperature of 21±2 °C and humidity of 50±5 %.
Animals were maintained on a 12-h light/dark cycle with
lights on at 7 am, unless otherwise stated. All experiments
were conducted in accordance with the UK (1986) Animal
(Scientific Procedures) Act (Project Licence 70/7072) and
the GSK Policy on the Care, Welfare and Treatment of Labo-
ratory Animals.
The numbers of animals used in each study were as fol-
lows: DID study in ethanol experienced animals, N=36; con-
ditioned taste aversion study, N=32; and receptor occupancy
study, N=40.
In the DID experiment, nine animals did not complete the
study. Of these animals, two were unwell at the time of pur-
chase and were removed from the study during the home cage
drinking phase. The remaining animals were removed during
the DID phase of the experiment due to ill health, although
this attrition was not evidently related to drug treatment.
Home cage ethanol consumption using the intermittent
ethanol escalation model
Home cage access to ethanol followed the intermittent
schedule described by Hwa et al. (2011). In brief, mice were
given intermittent access to ethanol for 24-h periods in a
two-bottle choice paradigm. Access to one bottle contain-
ing ethanol and one containing water was on Monday,
Wednesday and Friday. After 24 h, the bottles were re-
moved and weighed and replaced with two bottles of water.
The two water bottles remained in place until the next eth-
anol drinking session. The placement of bottles was alter-
nated before each ethanol drinking session to avoid side
preferences. Over the first four experimental sessions, eth-
anol concentration was increased in each successive session
(3, 6, 10 and 20 % (v/v)). The concentration was then main-
tained at 20 % for 3 weeks.
Mice were divided into two groups (group A (n=12) and
group B (n=15)) based on ethanol consumption during the
home cage ethanol escalation phase. Groups were balanced
so that there was no significant difference in alcohol consump-
tion between the two groups. These groups determined the
order in which the animals received drug treatment during
the test phase of the experiment.
Effect of GSK1521498 and naltrexone on ethanol
consumption using the DID procedure
Following home cage ethanol consumption using the intermit-
tent ethanol escalation model, and 1-week habituation to the
shifted light/dark cycle (lights off at 11 am), the animals were
trained to drink in the dark a 20 % ethanol solution from
spring loaded sipper tubes over a 3-week period, using a 2-
day intermittent DID procedure (Kamdar et al. 2007; see
Fig. 1 for an overview of the DID protocol).
In brief, mice were exposed to the DID procedure on 4 days
each week. Starting 2 h after lights off, water bottles were
removed and the cages placed on the experimental table.
The animals were left undisturbed for 1 h and then a spring-
loaded sipper tube attached to a 10-ml graduated pipette con-
taining the experimental solution was inserted into the nozzle
space in the cage lid, where the water bottle was usually
placed. Animals were left undisturbed for a further 2 h. After
this period, the volume of solution consumed was measured
by reading from the bottom of the liquid meniscus in the
pipette. Cages were returned to the holding rack and water
bottles were replaced.
Following the establishment of baseline ethanol DID con-
sumption (Fig. 1a), the animals were divided into two groups:
group A, receiving GSK1521498 (0, 0.1, 1 and 3 mg/kg; i.p.,
30 min pre-treatment) and saline (s.c., 10 min pre-treatment);
group B, receiving GSK1521498-vehicle (i.p., 30 min pre-
treatment) and naltrexone (0, 0.1, 1 and 3 mg/kg; s.c.,
10 min pre-treatment). In order to habituate the mice to the
injection protocol, prior to drug testing, mice were exposed to
three sessions where they received two injections of saline
(i.p. 30 min; s.c. 10 min prior to drinking; Tuesday, Friday,
Tuesday), followed by three additional injection sessions
where they received GSK1521498 vehicle (30 min i.p.; nal-
trexone vehicle, 10 min prior to drinking, s.c.; Friday, Tues-
day, Friday).
Next, over a 4-week period (phase 1; Fig. 1b), mice expe-
rienced two weekly baseline sessions, and two weekly test
sessions where they received two injections (GSK1521498
and saline, or GSK1521498-vehicle and naltrexone; Tuesday,
Friday). Analysis was carried out on the average consumption
across the two baseline and two injection sessions for each
week.
At the end of the 4 weeks of drug treatment, animals were
given a 3-week ethanol/injection-free period, to allow for drug
wash out. Subsequently, animals were then allocated to the
opposite drug group and DID behaviour was established over
a further 4-week period (phase 2; Fig. 1c). The protocol
followed the procedure described above except that for the
first 2 weeks, animals were not injected, and for the second
2 weeks, animals received two injections (GSK1521498-ve-
hicle, i.p., 30 min pre-treatment; saline, s.c. 10 min pre-treat-
ment) on Tuesday and Friday.
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Effect of GSK1521498 and naltrexone on sucrose
consumption using the DID procedure
Animals were given a further 3-week ethanol/injection-free
period before being tested to see if naltrexone or
GSK1521498 altered sucrose consumption (Fig. 1d). Using
the DID paradigm, animals had access to 2 % sucrose solution
in the sipper tubes. Animals were habituated to the procedure
for four sessions, without injection. The procedure then
followed stages as described above with baseline (non-
injection days) on Monday and Thursday and injection days
on Tuesday and Friday. On these days, the animals received
the two-injection protocol previously described. The doses
tested were 0, 0.1 and 1 mg/kg for both GSK1521498 and
naltrexone. The doses were administered in a pseudo-
random order with all mice receiving all doses. Each dose
was only tested for one session.
Effect of GSK1521498 and naltrexone on the development
of conditioned taste aversion to sucrose
Naive animals were divided into four groups, each of which
received either lithium chloride (256 mg/kg, 0.6 M, i.p.) or a
dose of GSK1521498 (vehicle, 1 or 3 mg/kg, i.p.).
The CTA experiment followed standard protocols previ-
ously used in our laboratory (Stephens and Dunworth 2000).
For 7 days, animals were water restricted to 4-h access to
water in their home cages (between 10 am and 2 pm). This
trained the animals to drink a large quantity of water during
this time period.
On days 1 to 3, animals were habituated to the spring-
loaded sipper tubes. Cages were removed from the holding
rack at 10 am and placed on the experimental table. Spring-
loaded sipper tubes attached to 10-ml graduated pipettes were
inserted into the nozzle space in the cage lid, where the water
bottle was usually placed. Animals were allowed to drink
from the sipper tube for 30 min. The amount consumed was
recorded by reading from the bottom of the liquid meniscus in
the pipette. Cages were then returned to the holding rack, but
animals were not given access to their water bottle for a further
1 h. Animals then had access to water for 3.5 h (between 11.30
am and 3 pm). Animals were allocated to test group based on
the average amount that they had consumed over days 2 and 3
of this baseline period so that baseline consumption was
matched across treatment groups.
On day 4, the conditioning day, cages were placed on the
experimental table and sipper tubes, containing 10 % sucrose
solution, were inserted into the cage for 30 min. Fluid con-
sumption was measured. Animals were then immediately
injected with either LiCl or GSK1521498 (as described
above). Animals were returned to their home cage for 1 h
before access to water bottles for 3.5 h (as on days 1 and 2).
Day 5, the test day, mimicked day 4 with the exception that
animals did not receive injections. Day 6 was used to test the
specificity of the conditioning for sucrose. The procedure
mimicked day 5, except that water replaced sucrose in the
sipper tubes.
Receptor occupancy
Receptor occupancy was analysed using the protocol previ-
ously described by Codd et al. (2010). Animals were divided
into two groups. The first group were treated with
GSK1521498 (0, 0.1, 1, 3 or 10 mg/kg, i.p. (four mice per
treatment group)) and killed by decapitation 1 h later. The
second group were treated with naltrexone (0, 0.1, 1, 3 or
10 mg/kg, s.c. (four mice per group) and killed by decapita-
tion, following cervical dislocation, 40 min later. These tim-
ings were chosen to match those in the drinking in the dark
experiment.
Home cage ethanol consumption using 
escalation model
Establish DID for 20% EtOH
DID: Group A
Inj 1: GSK1521498
Inj 2: saline
DID: Group B
Inj 1: GSK vehicle
Inj 2: naltrexone
Re-establish DID for 20% EtOH
DID: Group A
Inj 1: GSK vehicle
Inj 2: naltrexone
DID: Group B
Inj 1: GSK1521498
Inj 2: saline
Re-establish DID for 2% sucrose
DID
(Protocol as for EtOH DID)
P
ha
se
 1
P
ha
se
 2
a 
b
c
d
Fig. 1 Overview of the experimental protocol. The experiment was
divided into four parts: a animals consumed ethanol in their home cage
using the ethanol escalation model; b phase 1: following the
establishment of baseline ethanol consumption using the DID method
animals were divided into two groups with group A receiving
GSK1521498 and group B receiving naltrexone as the test compound;
c phase 2: following a 2-week wash-out period, DID was re-established
and a cross-over design was employed such that group A received
naltrexone and group B received GSK1521498 as the test compound; d
compound specificity was tested using a 2 % sucrose DID protocol
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On decapitation, the brains were removed, immediately
frozen in pre-cooled 2-methylbutane (temperature −30 to
−40 °C), and stored at −80 °C for up to 7 days. Brain slices
(14-μm coronal sections) were cut at approximately +
1.54 mm from bregma (Paxinos and Franklin 2001). Adjacent
slices were mounted on glass slides and incubated at room
temperature for 10 min with 5 nM [3H]DAMGO (specific
activity 1850 GBq/mmol; PerkinElmer, UK) in buffer
(50 mM Tris/HCl, 5 mM MgCl2, 0.1 %w/v bovine serum
albumin, pH 7.4) containing 40 μg/ml autoclaved bacitracin,
washed twice (at 4 °C) in buffer for 5 min, followed by
deionised water (2×5 s), air dried and exposed to BAS-
TR2025 imaging plates (Fuji Photo Film Co., Japan) for
3 weeks. Autoradiograms were generated using the Bio-
image Analyzer BAS5000 (Fuji Photo Film Co., Japan), and
the region of interest measured integrally by computer-
assisted microdensitometry (MCID basic, Imaging Research,
Canada). Photostimulated luminescence (PLS) per mm2
values were converted to the corresponding [3H]DAMGO
concentration, expressed as fmol/mg brain tissue by reference
to [3H] standards (Microscales, Amersham) on the same im-
aging plate. Of four slides for each brain, two were used for
determination of total binding and two for non-specific bind-
ing (NSB), in the presence of 1 μM DAMGO, allowing spe-
cific binding to be calculated by subtraction. Percentage re-
ceptor occupancy (RO) of each GSK1521498- and
naltrexone-treated mouse was calculated as RO(%)=[1−
SBT/SBV]×100, where SBT is the specific binding in each
individual animal treated with drug, and SBV is the mean SB
for animals treated with vehicle. Occupancy data were calcu-
lated by non-linear regression analysis using GraphPad Prism
V5.0., whereby RO(%)=[ROmax×(D)
γ]/[(ROD50)
γ+(D)γ].,
where D is the dose, ROD50 is the dose giving 50 % maximal
occupancy (RODmax), and γ is the Hill coefficient of this
function.
Drug preparation
A stock solution of GSK1521498 (4 mg/ml, expressed in
terms of the free base) in an acidified hydroxypropyl beta-
cyclodextrin (HPBCD)-containing vehicle was provided by
GlaxoSmithKline. All pre-prepared solutions were kept fro-
zen throughout the duration of the experiment.
Stock GSK1521498 and vehicle blank solutions were
thawed and diluted in the phosphate-buffered diluent to
yield a 1 mg/ml solution. For the phosphate buffer, 4 g
sodium chloride, 0.1 g potassium chloride, 0.44 g monoba-
sic potassium phosphate and 0.241 g dibasic sodium phos-
phate (anhydrous) were diluted in 500 ml distilled water
and mixed well.
This 1 mg/ml solution of GSK1521498 was diluted to pro-
duce solutions of 0.3, 0.1 and 0.01 mg/ml, using a serial dilu-
tion technique. Diluted solutions were filtered through a 0.2-
micron filter prior to administration to the mice. Injection vol-
umes were 10 ml/kg throughout. Final injection concentra-
tions for GSK1521498 were vehicle, 0.1, 1 or 3 mg/kg, i.p.,
30 min pre-treatment. Solutions were refrigerated and used
within 48 h of preparation.
Naltrexone hydrochloride (Sigma-Aldrich, UK) was dis-
solved in saline to produce a 1 mg/ml solution. This
1 mg/ml solution was diluted to produce solutions of 0.3 and
0.1 mg/ml, using a serial dilution technique. Diluted solutions
were filtered through a 0.2-micron filter prior to administra-
tion to the mice. Injection volumes were 10 ml/kg throughout.
Final injection concentrations for naltrexone were vehicle,
0.1, 1 or 3 mg/kg, s.c., 10 min pre-treatment. Solutions were
refrigerated after preparation and were used within 1 week of
preparation.
Lithium chloride (LiCl: Sigma-Aldrich) was dissolved in
saline to give a final concentration of 25.6 mg/ml. Injection
volumes were 10 ml/kg throughout. The final injection dose
for LiCl was 256 mg/kg, i.p. Solutions were refrigerated and
used within 24 h of preparation.
Statistical analysis
SPSS and SAS software were used for data analysis. Data
transformations were applied for repeated measures ANOVA
as described below to best meet the required assumption of
sphericity. Residuals were observed to have magnitude ap-
proximately proportional to the mean. In these circumstances,
it is appropriate to log-transform the data prior to analysis to
normalise the size of the residuals. Not transforming would
give more influence to high-value outliers and decrease preci-
sion around means at low drinking levels. Significant factorial
effects from repeated measures ANOVAwere explored using
post hoc t tests.
Home cage ethanol drinking data were converted from
millilitres to g EtOH/kg body weight for analysis. Consump-
tion across the 12 home cage intermittent access drinking ses-
sions was analysed using a repeated measures ANOVA with
factors for animal group (A or B; between-subject) and drink-
ing session (within-subject).
For the DID experiments, drinking data were converted
from millilitres to g EtOH/kg body weight and log-
transformed for analysis. Data were combined across phases
1 and 2 and were analysed using a repeatedmeasures ANOVA
with factors for drug, dose, phase and session (non-injection
baseline vs test) and two- and three-way interactions (all with-
in-subject). Magnitudes of effect were estimated with 95 %
confidence intervals (quantified as fold changes following
back-transformation of the log-transformation).
In order to make valid comparisons between the two test
drugs, ethanol consumption data were further analysed taking
into account receptor occupancy estimated from receptor
binding data. Firstly, the drug dose–receptor occupancy data
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were plotted and the curves used to derive two doses giving
rise to similar degrees of receptor occupancy (which did not
differ significantly when compared using an independent sam-
ples t test). The reduction of ethanol intake by these equivalent
occupancy doses was then compared using pairwise contrasts
within the ANOVA.
For the DID sucrose consumption data, data were analysed
in mls of solution consumed. Acquisition data were analysed
using a repeated measures ANOVA across the first four ses-
sions to ensure that the four treatment groups were matched
for consumption before treatment. Effect of drug was mea-
sured for each drug separately using a repeated measures
ANOVAwith dose as the within-subject factor.
For the CTA experiments, LiCl data were analysed using a
paired t test across the two sessions. Data from animals treated
with GSK1512498 were analysed with a repeated measures
ANOVA with factors for dose (between-subject) and session
(within-subject).
Results
Home cage alcohol consumption
Figure 2 shows that daily ethanol intake increased as concen-
tration was increased (significant main effect of session: F11,
286=75.58, p<0.001). It is consistent with previous studies
that the animals consumed more ethanol over successive ses-
sions. Consumption stabilised at the 20 % concentration, the
average ethanol consumption over the final three sessionswith
20% ethanol being 21.05±1.14 g/kg (n=27).When the group
status (A or B) coding order of drug administration was in-
cluded as a covariate, there was no main effect or interaction
involving order (main effect of order: F1,25=1.362, p=0.254;
order × session F11,275=0.460, p=0.808) showing that the
groups were balanced for alcohol consumption before drug
testing began.
Effect of GSK1521498 and naltrexone on ethanol
consumption
Figure 3 shows average weekly ethanol consumption during
DID on both the day prior to drug administration (baseline)
and on drug administration days. Table 1 presents the fold
changes in ethanol consumption (compared to non-injection
days and placebo sessions). The injection procedure produced
a small reduction in drinking when compared to non-injection
baseline days, but there was no difference among the groups,
suggesting that although the injection procedure reduced al-
cohol consumption, there was no evidence that the order of
dosing had effects. There was also a significant difference in
consumption between phases (F1,125=34.7, p<0.01), with
greater consumption in phase 1. However, there were no
significant interactions between phase and other effects of
interest, and a sensitivity analysis restricted to only phase 1
data gave similar estimates to those in Table 1, implying that
the fold reductions in drinking were consistent irrespective of
the baseline drinking level within each phase.
Both compounds were associated with a dose-dependent
decrease in ethanol consumption. For GSK1521498, post
hoc analysis following a significant session by dose interac-
tion (F3,78=6.56, p<0.01) showed that this was due to a dose-
dependent effect of drug treatment days only (F3,78=10.106,
p<0.001). Each dose of GSK1521498 significantly reduced
ethanol intake when compared with vehicle-treated animals
(t26>2.76, p<0.01 for all comparisons). In the case of naltrex-
one, there was also a significant session by dose interaction
(F3,78=4.28, p<0.01), which was once again attributable to a
dose-dependent effect of drug treatment days only (F3,78=
3.56, p<0.05). When compared with vehicle treatment, only
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Fig. 2 Animals were exposed to ethanol in the home cage using the
ethanol escalation procedure. Consumption increased with ethanol
concentration and stabilised at the 20 % ethanol solution (average
consumption 20.89±2.08 and 21.72±1.35 g/kg in the two groups over
the final three sessions). There were no differences between the groups.
Bars indicate standard errors of the mean (SEM)
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Fig. 3 Ethanol consumption following administration of GSK1521498
or naltrexone when the data were combined across phases 1 and 2 of the
study: both GSK1521498 and naltrexone produced a significant decrease
in ethanol consumption, but this effect was less pronounced following
naltrexone administration. Baseline refers to consumption on day prior to
respective injection day. Data points for the 0 mg/kg dose have been
offset to allow the reader to interpret the error bars.*p<0.05,
significantly different from vehicle. Bars indicate SEM. The same data,
plotted as percentage change from baseline, are shown in Supplementary
Fig. 1
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the 0.1 and 3 mg/kg dose significantly reduced ethanol con-
sumption (0 vs 0.1 mg/kg, t26=2.23, p<0.05; 0 vs 3 mg/kg,
t26=2.96, p<0.01). This decrease in consumption was smaller
and not statistically significant when animals were adminis-
tered the intermediate dose of 1 mg/kg (t26=1.25, p>0.05).
Initial inspection of Fig. 3 and Table 1 suggests apparently
different interpretations; the 3 mg/kg dose of naltrexone re-
duced alcohol intake by 1.2 g/kg, whereas the reduction at-
tributable to GSK1521498 at the same dose is less, approxi-
mately 1 g/kg. Nevertheless, when considered as fold changes
from baseline, taking fold changes of the simple group means
gives 5.2 for GSK1521498 and 3.0 for naltrexone. These
values are close to the results of the repeated measures
ANOVA in Table 1 (5.3 for GSK1521498 and 2.7 for naltrex-
one) given that the ANOVA adjusts for other factors such as
phase and the within-animal repeated measures.
Receptor occupancy analysis
In order to compare intrinsic efficacy of the two drugs, recep-
tor occupancy was expressed as a function of drug dose for
each drug. Figure 4a shows that naltrexone gave rise to greater
receptor occupancies than GSK1521498 over the dose ranges
and routes of administration used, suggesting a greater poten-
cy. In order to compare the relative efficacies of the two sub-
stances, we chose to compare drug effects at doses of each
drug giving rise to similar receptor occupancy in the range 70–
75 %. For naltrexone, this degree of occupancy corresponded
to a dose of 0.1 mg/kg, s.c., whereas an i.p. dose of 3 mg/kg of
GSK1521498 gave rise to the same occupancy of striatal re-
ceptors (t6=0.34, p=0.749). Figure 4b shows that at this re-
ceptor occupancy, GSK1521498 reduced ethanol intake to a
greater extent than naltrexone. Figure 4c presents these data as
fold change from baseline (t145=3.73, p<0.001).
Effect of GSK1521498 and naltrexone on sucrose
consumption
Specificity of the drug effect in reducing ethanol intake was
tested using a 2 % sucrose solution in the sipper tubes. During
the acquisition phase (first four sessions), animals were not
injected. There was a significant increase in sucrose across this
period (F3,75=20.01, p<0.001), which stabilised after session
2 (consumption on day 4: 1.6±0.2 ml). Figure 5 shows that
both GSK1521498 and naltrexone significantly reduced su-
crose consumption at a dose of 1 mg/kg but not 0.1 mg/kg
(main effect of GSK1521498: F2,52=8.05, p<0.001; post hoc
paired t test, 0 vs 1 mg/kg, t26=3.11, p<0.01; main effect of
naltrexone: F2,50=3.86, p<0.05; post hoc paired t test, 0 vs
1 mg/kg, t25=2.28, p<0.05).
Conditioned taste aversion
A conditioned taste aversion to LiCl was seen as a significant
decrease in sucrose consumption on the test day compared
with the conditioning day (t7=4.24, p<0.005; Fig. 6).
GSK1521498 produced a conditioned taste aversion only
at the highest dose tested (Fig. 6). Repeated measures
ANOVA demonstrated a significant main effect of dose (F2,
21=6.53, p<0.01), session (F1,21=21.03, p<0.001) and a dose
by session interaction (F2,21=15.45, p<0.001). Post hoc anal-
ysis showed that GSK1521498 3 mg/kg produced a signifi-
cant decrease in sucrose consumption on the test day when
compared with the conditioning day (p<0.001). A marginal
effect was seen with a dose of 1 mg/kg (p=0.06), and no effect
was seen after a vehicle injection (p=0.266).
There was no change in water consumption post-condition-
ing, when compared with baseline drinking levels, in the LiCl-
treated animals (p=0.741). Following GSK1521498 treat-
ment, there was a slight increase in water consumption post-
conditioning (main effect of session: F1,21=4.97, p<0.05) but
this did not reach significance at any single dose.
Discussion
The mu-opioid receptor system has been shown to play a
fundamental role in reward processes. Activation of this sys-
tem, by both primary and secondary reinforcers, has been
implicated in mediating reward and attributing incentive
Table 1 Fold change in ethanol consumption when animals were administered GSK1521498 or naltrexone when compared with baseline
consumption measures
Dose (mg/kg) Fold decrease in ethanol consumption vs non-injection baseline Fold decrease in ethanol consumption vs 0 mg/kg dose
(baseline-adjusted)
GSK1521498 Naltrexone GSK1521498 Naltrexone
0 1.5 (1.1, 2.1) 1.4 (1.0, 2.0) – –
0.1 2.1 (1.5, 2.9) 2.1 (1.5, 3.0) 1.4 (0.9, 2.2) 1.5 (0.9, 2.5)
1 3.3 (2.4, 4.6) 2.5 (1.8, 3.5) 2.2 (1.4, 3.5) 1.8 (1.1, 2.9)
3 5.3 (3.8, 7.4) 2.7 (1.9, 3.9) 3.5 (2.2, 5.6) 1.9 (1.2, 3.1)
Values in brackets are 95 % confidence intervals
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salience to cues associated with delivery of the reinforcer.
Therefore, the opioid system has been suggested as a primary
target for therapeutic intervention in eating disorders and drug
abuse. Indeed, one of the main current pharmacological treat-
ments for alcoholism, naltrexone, has antagonistic effects at
MOPr. However, as this treatment has only limited success in
treatment of alcohol dependence, further investigation into
compounds acting on this target is warranted.
GSK1521498 is currently being developed for disorders of
compulsive consumption, including alcohol dependence
where patients have a long history of alcohol exposure.
Hence, in the current study, we compared the ability of
GSK1521498 to that of naltrexone in reducing ethanol con-
sumption in ethanol-experienced animals using a pre-clinical
mouse model. Both GSK1521498 and naltrexone reduced
ethanol consumption in a dose-dependent manner. A potential
weakness of the current study is that we chose to give the two
drugs by different routes in order to obtain similar pharmaco-
kinetic profiles, and to align with dosing regimens used in
previous studies of GSK1521498 and naltrexone (Ignar et al
2011; Giuliano et al 2012, 2013). This dosing regimen thus
allowed comparison of both drugs’ effects on alcohol con-
sumption to their effects at the same doses across a wide range
of other animal models of eating behaviour, drug seeking and
drug-taking behaviours. However, this approach has the dis-
advantage that direct comparison of relative potencies of the
two drugs is not possible. We sought to overcome this poten-
tial weakness by determining ex vivo receptor occupancies
across the dose range chosen, allowing us to compare the
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pharmacodynamic effects at similar occupancy levels, thus
controlling for potential differences between the two drugs
in absorption, metabolism or blood-brain barrier penetration.
At doses at which both drugs achieved approximately 70–
75 % receptor occupancy, the reduction in alcohol consump-
tion was significantly greater in animals treated with
GSK1521498 compared with naltrexone (2.5-fold difference).
Analysis comparing drug action at the same receptor occu-
pancy level is seldom performed and yet offers a potential
in vivo measure of drug relative efficacy. This is especially
important when drugs are administered by different routes and
with different pre-treatment times as in the present experi-
ment. Nevertheless, only one pair of doses (0.1 mg/kg sc
naltrexone and 3mg/kg i.p. GSK1521498) was approximately
matched for 70–75 % receptor occupancy, and in future stud-
ies, it would be valuable to plan dosing a priori to match for
receptor occupancy over a wider range of occupancy levels so
that differential intrinsic efficacy can be assessed at more clin-
ically relevant doses achieving more complete blockade of the
mu-opioid receptor.
This ability to achieve a greater effect at equivalent occu-
pancies suggests that GSK1521498 may possess a higher in-
trinsic efficacy than naltrexone in opposing MOPr function.
Higher intrinsic efficacy might come about if naltrexone pos-
sesses partial agonist properties at the MOPr (Kelly et al.
2014), and GSK1521498 is either a neutral antagonist (Kelly
et al. 2014) or possesses partial inverse agonism at MOPR1
(Ignar et al. 2011). Although Kelly et al. (2014) failed to find
evidence for inverse agonist activity at endogenous MOPr in
brain tissue from drug-naive mice (Kelly et al. 2014),
GSK1521498 did demonstrate mild inverse agonist activity
in brain tissue from mice that had received morphine pre-
treatment. Under the same experimental conditions, naltrex-
one did not behave as an inverse agonist (Kelly et al. 2014). It
might be worth noting that the mice in our study had been
exposed to considerable ethanol intake prior to the pharmaco-
logical experiments, but we are unaware of data to suggest that
such ethanol exposure mimics morphine exposure in increas-
ing constitutive activity at MOPrs, thus allowing inverse
agonism to be revealed.
A complexity arises in the interpretation of the key exper-
iment in this study in that the injection procedure produced a
reduction in drinking when compared to non-injection base-
line days, even when animals were dosed with vehicle and no
active drug. Although the reduction is relatively small and
similar for both vehicles studied, there is some variation in
the consumption on non-injection days at different doses
which could not be ignored in the analysis since failing to
adjust for non-injection consumption would lead to
overestimating the effect of GSK1521498 relative to naltrex-
one. It was also observed that when consumption was low, the
within- and between-animal variability was also low, and vice
versa at high consumptions. These factors together
necessitated a log-transformation of consumption data prior
to ANOVA and reporting results as fold changes adjusting
for both non-injection consumption and vehicle consumption.
The results in the present study show a slight decrease in
the effectiveness of naltrexone when compared with other
studies in the literature. Indeed, Kamdar et al. (2007) reported
that naltrexone, 1 mg/kg, decreased consumption of 20 %
ethanol over a 2-h period using the DID protocol. The de-
creased potency in the present study may be due to the repeat-
ed administration of naltrexone, which has been shown to lead
to a reduction in its ability to reduce ethanol intake (Middaugh
and Bandy 2000). Indeed, Phillips et al. (1997) reported an
increase in ethanol intake following chronic treatment with
naltrexone in C57BL/6J mice.
It should also be noted that both GSK1521498 and naltrex-
one, at a dose of 1 mg/kg, significantly reduced sucrose con-
sumption, although the magnitude of reduction was similar for
both drugs. This result was not surprising as GSK1521498 has
been shown to decrease both nocturnal food consumption and
preference for sucrose containing solutions in animal studies
(Giuliano et al. 2012; Ignar et al. 2011), and to decrease the
hedonic response to sweetened dairy products in humans
(Ziauddeen et al. 2013). Naltrexone has also been shown to
decrease food intake (for review, see Berner et al. 2011). How-
ever, in the study by Kamdar and colleagues (2007), where a
similar DID protocol was used, naltrexone did not reduce
consumption of either 10 % sucrose or plain water. Although
no data currently exist in this field, it would be interesting to
see if repeated treatment with naltrexone enhances its effect on
sucrose consumption whilst diminishing its effect on ethanol
consumption. Although there was evidence for higher efficacy
of GSK1521498 versus naltrexone on alcohol consumption,
there was no significant difference in the effects of the two
drugs on sucrose consumption. A previous study found that
both drugs had effects on food seeking and binge-like eating
behaviours, and GSK1521498 specifically had effects on in-
centive motivation for chocolate (Giuliano et al. 2012). Fur-
ther studies will be needed to clarify whether GSK1521498
differs significantly from naltrexone in its effects on sweet and
fat food seeking and consumption.
Besides these data on alcohol and sucrose consumption, the
current study does not provide new results from models of
other consummatory behaviours; but the same drugs have
been studied at the same doses in several prior studies of
eating behaviour, chocolate-, cocaine- and heroin-seeking be-
haviours, and cocaine and heroin self-administration (Ignar
et al 2011; Giuliano et al 2012, 2013). Consistently,
GSK1521498 has been shown to attenuate behavioural mea-
sures of drug or food reward-seeking and to reduce consump-
tion of food and heroin. In clinical studies of healthy volun-
teers and binge-eating obese patients (Nathan et al. 2012a, b).
GSK1521498 has also been shown to reduce the hedonic and
consummatory response to food (especially high fat foods)
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and to reduce brain functional activation measured by fMRI
following oral administration of a small quantity of
(rewarding) fruit juice during scanning (Rabiner et al. 2011).
On this basis, we suggest that GSK1521498 does not selec-
tively modulate alcohol-related behaviours but has more gen-
eral effects on opioid-mediated reward signalling in the brain
that are behaviourally manifest by reduced seeking and con-
suming of many rewarding substances.
Decreases in consumption of ethanol (or other rewards)
could be due to non-specific effects, such as general malaise
following the injection, and there is some evidence to suggest
that naltrexone may support conditioned taste aversion (CTA)
at relatively low doses (Parker and Rennie 1992). Consistent
with that notion, administration of GSK1521498 following
exposure to a novel sucrose solution, reduced consumption
of that solution, but not of water, on a subsequent occasion.
This is consistent with GSK1521498 possessing aversive
properties that become conditioned to the taste of sucrose.
Nevertheless, the ability of GSK1521498 to support a condi-
tioned taste aversion was seen only at a high dose of 3 mg/kg
(at which it was more effective than a standard dose of LiCl),
whereas its ability to reduce ethanol consumption was already
apparent at a dose of 0.1 mg/kg (Fig. 3). It thus seems unlikely
that GSK1521498’s effects on alcohol consumption simply
reflect induction of malaise.
In summary, the current study showed that both
GSK1521498 and naltrexone reduce ethanol consumption in
an experimental model of drinking to excess, with evidence
for greater intrinsic efficacy of GSK1521498.
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